http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#Head http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#assertion http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#provenance http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#pubinfo http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#assertion http://purl.obolibrary.org/obo/DOID_409 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_409 http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00973 http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association http://www.w3.org/2000/01/rdf-schema#label "Ezetimibe Tablet is contraindicated in the following conditions: The combination of Ezetimibe Tablets with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels. Women who are pregnant or may become pregnant. Because statins decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, Ezetimibe Tablets in combination with a statin may cause fetal harm when administered to pregnant women. Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy. [See Use in Specific Populations ( 8.1 Nursing mothers. Because statins may pass into breast milk, and because statins have the potential to cause serious adverse reactions in nursing infants, women who require Ezetimibe Tablets treatment in combination with a statin should be advised not to nurse their infants [see Use in Specific Populations ( 8.3 Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including anaphylaxis, angioedema, rash and urticaria have been reported with Ezetimibe Tablets [see Adverse Reactions ( 6.2 * Statin contraindications apply when Ezetimibe Tablet is used with a statin: Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels ( 4 5.2 Women who are pregnant or may become pregnant ( 4 8.1 Nursing mothers ( 4 8.3 Known hypersensitivity to product components ( 4 6.2" http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00973 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#provenance http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#pubinfo http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#sig http://purl.org/nanopub/x/hasSignature EXmqaUdQyZRGcJGF0oQnB2YCW08ZljzJuMC9toTdN460BYU9PsStW5yeTUtEnmwImCMOmXi4HnKVKPF8KtbQ4KlDB/jfCBBOSdl2UJj2PEHk2b6HpiJJKygGnp4f/9zDIPn3UyHf9e/BnhamhlCMs+meh80QjupE6WXkc1Yuino= http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM http://purl.org/dc/terms/created 2021-08-23T12:34:30.728+02:00 http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY